Common use

Cyclophosphamide is a powerful alkylating chemotherapy agent and immunosuppressant that belongs to the nitrogen mustard class of cytotoxic drugs. It is one of the most widely used and versatile anticancer medications in modern oncology. As a prodrug, Cyclophosphamide itself is pharmacologically inactive — it requires metabolic activation in the liver by cytochrome P450 enzymes, which convert it into its two active metabolites: phosphoramide mustard and acrolein. Phosphoramide mustard is the primary cytotoxic compound responsible for the anticancer effect, working by cross-linking DNA strands within rapidly dividing cells, which prevents proper DNA replication and ultimately leads to cell death (apoptosis). While this mechanism primarily targets rapidly proliferating cancer cells, it also affects healthy cells that divide quickly, including those in the bone marrow, gastrointestinal tract, and hair follicles, which accounts for many of the drug's characteristic side effects.

Beyond its cytotoxic activity, Cyclophosphamide possesses significant immunosuppressive properties, making it valuable not only in cancer treatment but also in managing severe autoimmune conditions. Oncologists prescribe Cyclophosphamide for a broad range of malignancies, including malignant lymphomas (lymphocytic lymphoma, histiocytic lymphoma, Hodgkin's lymphoma, Burkitt lymphoma, and mixed-type lymphoma), multiple myeloma, various leukemias (chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelocytic leukemia, and acute lymphoblastic leukemia in children), neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. As an immunosuppressant, it is used to treat severe lupus nephritis, granulomatosis with polyangiitis (Wegener's), and other refractory autoimmune diseases. When you buy Cyclophosphamide online, you access a cornerstone chemotherapy drug that has been saving lives in cancer treatment for over six decades.



Dosage and direction

Cyclophosphamide dosing is highly individualized and depends on the type of cancer being treated, the patient's body weight and surface area, overall health status, kidney and liver function, and the specific treatment protocol being followed. For intravenous administration, the typical dose ranges from 40 to 50 mg/kg of body weight, given in divided doses over 3 to 5 days. Oral Cyclophosphamide is usually dosed at 1 to 5 mg/kg daily, though this varies considerably based on the treatment regimen. Dosage adjustments are routinely made based on regular blood tests, particularly white blood cell counts, to minimize the risk of severe myelosuppression. When taking Cyclophosphamide orally, swallow the tablets whole with a large glass of water, with or without food, preferably in the morning. Adequate hydration throughout treatment is critically important to prevent hemorrhagic cystitis — drink at least 2 to 3 liters of fluid daily and empty your bladder frequently, including before bedtime. Your oncologist will monitor your blood counts, kidney function, and overall health closely throughout treatment.



Precautions

Extra caution is required when administering Cyclophosphamide to patients with existing myelosuppression (low blood cell counts), liver or kidney disorders, or those who have previously undergone radiation therapy or other chemotherapy regimens, as these factors can significantly increase the risk of toxicity. Regular monitoring of complete blood counts and urinalysis (checking for the presence of red blood cells in urine, which may indicate bladder damage) is mandatory during treatment. Women of childbearing age must use highly reliable contraception throughout Cyclophosphamide therapy and for at least 12 months after completing treatment, as this drug is a known teratogen with the potential to cause severe birth defects. Male patients should also be counseled about the risk of permanent infertility and may wish to consider sperm banking before starting treatment. Report any signs of infection, unusual bleeding or bruising, blood in urine, persistent cough, or unexplained fatigue to your healthcare provider immediately.



Contraindications

Cyclophosphamide is contraindicated in patients with known hypersensitivity to the drug, severe pre-existing bone marrow suppression (myelosuppression), active urinary tract infections, urinary outflow obstruction, and active hemorrhagic cystitis. Pregnancy and breastfeeding are absolute contraindications due to the drug's teratogenic and mutagenic properties. Patients with severely compromised immune function or active severe infections should not begin Cyclophosphamide therapy until these conditions are adequately managed.



Side effects

Cyclophosphamide carries significant potential for serious side effects due to its cytotoxic mechanism. The most common side effects include nausea and vomiting (which can usually be managed with antiemetic medications), temporary hair loss (alopecia), bone marrow suppression leading to increased vulnerability to infections (leukopenia, neutropenia), anemia, and thrombocytopenia (low platelet count with increased bleeding risk). Hemorrhagic cystitis — inflammation and bleeding of the bladder caused by the metabolite acrolein — is a characteristic adverse effect that can be prevented through aggressive hydration and, in some protocols, co-administration of mesna (a protective agent). Long-term risks include the development of secondary malignancies, particularly bladder cancer, lymphoma, and acute myeloid leukemia, which may appear several years after treatment completion. Other reported side effects include mouth sores (stomatitis), loss of appetite, darkening of skin and nails, changes in taste, cardiotoxicity at high doses, lung toxicity (pulmonary fibrosis), and impaired fertility in both men and women.



Drug interaction

Cyclophosphamide interacts with numerous medications, and your oncologist must be informed of all drugs you are taking. Doxorubicin (Adriamycin) can increase the cardiotoxic effects of Cyclophosphamide when used together. Allopurinol may enhance the myelosuppressive effects of Cyclophosphamide. Phenobarbital and other hepatic enzyme inducers can accelerate the conversion of Cyclophosphamide to its active metabolites, potentially increasing both efficacy and toxicity. Patients who have undergone adrenalectomy and are on replacement steroid hormones may require dosage adjustments when taking Cyclophosphamide concurrently. Live vaccines should be avoided during Cyclophosphamide therapy due to the risk of generalized, potentially fatal infection from the immunosuppressed state. Warfarin anticoagulant effects may be altered, requiring closer monitoring of coagulation parameters.



Missed dose

If you miss a dose of oral Cyclophosphamide, take it as soon as you remember, provided it is not too close to the time for your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule. Never take a double dose or extra doses to make up for a missed one. If you are uncertain about what to do, contact your oncologist or pharmacist for guidance. Consistent dosing is important for maintaining therapeutic drug levels.



Overdose

While specific overdose symptoms of Cyclophosphamide may vary, an overdose would be expected to cause exaggerated versions of the drug's known side effects, particularly severe bone marrow suppression, hemorrhagic cystitis, and potentially fatal infections. If you suspect you have taken more Cyclophosphamide than prescribed, contact your oncologist or go to the nearest emergency room immediately. There is no specific antidote for Cyclophosphamide overdose, and treatment is supportive, including blood transfusions, colony-stimulating factors, and aggressive hydration.



Storage

Store Cyclophosphamide tablets at room temperature between 68-77 degrees F (20-25 degrees C). Protect from heat, direct sunlight, and moisture. Keep this cytotoxic medication out of the reach of children and pets. Storage in a bathroom is not recommended due to humidity. Handle Cyclophosphamide tablets with care — wash hands thoroughly after touching them, and do not crush or break the tablets. Dispose of unused medication through a proper pharmaceutical waste program, not through household trash or wastewater.



Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.